Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases
Investigative Opthalmology & Visual Science · 2023-05-30 · 64 (5) · 28
DOI: 10.1167/iovs.64.5.28 ↗At a glance
Übersichtsarbeit in Investigative Opthalmology & Visual Science, published on 2023-05-30. Written by Dhyana Sharma and 2 co-authors. Institution: Biotherapeutics and Advanced Therapies, Research and Development, Medicines and Healthcare products Regulatory Agency, London, United Kingdom. Major MEDLINE topics: Diabetic Retinopathy, Macular Edema, Wet Macular Degeneration. Cited 99 times so far (Crossref); 121 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
The purpose of this study was to evaluate clinical reports of response-loss in patients with neovascular eye diseases, such as neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), after repeated anti-vascular endothelial growth factor (VEGF) therapy. To assess experimental evidence of associations of other angiogenic growth factors and endothelial glycolytic pathways with the diseases and to propose the underlying mechanisms.
Methods
Review of published clinical studies and experimental investigations.
Results
Intravitreal injection of anti-VEGF biologic drugs (e.g. bevacizumab, ranibizumab, and aflibercept) is the front-line treatment for neovascular AMD and DME, and acts by halting the progression of excess blood vessel growth and leakage. Despite favorable clinical results, exudation returns in a number of patients after repeated administrations over time. Patients suffering from disease recurrence may have developed an acquired resistance to anti-VEGF therapy. We have analyzed clinical and preclinical findings on changes to angiogenic signaling pathways following VEGF-targeted treatment and hypothesize that switching to alternative pathways could potentially bypass VEGF blockade, accounting for development of resistance to anti-VEGF therapy. We have also discussed potential reprogramming of ocular endothelial glycolysis in response to VEGF antagonism and proposed that metabolic adaptations could impair blood-retinal barrier function, counteracting the clinical efficacy of VEGF-targeted therapies and contributing to a decline of response to them.
Conclusions
Future studies of the mechanisms proposed in this review may shed some light on how these adaptations result in the development of acquired resistance to anti-VEGF therapy, which should help discover new therapeutic strategies for overcoming anti-VEGF resistance and improving clinical efficacy.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Biotherapeutics and Advanced Therapies, Research and Development, Medicines and Healthcare products Regulatory Agency, London, United Kingdom.
- Centre for Cardiometabolic and Vascular Science, Division of Medicine, University College London, London, United Kingdom.
Cite
APA
Sharma, D., Zachary, I., & Jia, H. (2023). Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases. Investigative Opthalmology & Visual Science, 64(5), 28. https://doi.org/10.1167/iovs.64.5.28
Vancouver
Sharma D, Zachary I, Jia H. Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases. Investigative Opthalmology & Visual Science. 2023;64(5):28. doi:10.1167/iovs.64.5.28
BibTeX
@article{Sharma2023,
author = {Sharma, Dhyana and Zachary, Ian and Jia, Haiyan},
title = {Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases},
journal = {Investigative Opthalmology & Visual Science},
year = {2023},
volume = {64},
number = {5},
pages = {28},
doi = {10.1167/iovs.64.5.28}
}
EUVIMED